Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $10,916.08 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 404 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $10,916.08. Following the transaction, the executive vice president now owns 262,715 shares in the company, valued at approximately $7,098,559.30. This represents a 0.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

BioLife Solutions Stock Down 3.9 %

BLFS stock opened at $26.61 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a 50 day simple moving average of $25.99 and a 200-day simple moving average of $24.29. The company has a market capitalization of $1.23 billion, a P/E ratio of -25.10 and a beta of 1.92. BioLife Solutions, Inc. has a twelve month low of $14.50 and a twelve month high of $28.88.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Fred Alger Management LLC raised its stake in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares in the last quarter. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares during the last quarter. Geode Capital Management LLC raised its stake in BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in BioLife Solutions by 9.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after buying an additional 66,422 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in shares of BioLife Solutions by 81.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after acquiring an additional 262,504 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on BLFS. Benchmark reissued a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. KeyCorp upped their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Northland Securities upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions presently has a consensus rating of “Moderate Buy” and an average target price of $29.43.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.